Holen Sie sich die Stockscreener-App
6.81
2.00%
0.18
Schlusskurs vom Vortag:
$6.63
Offen:
$6.62
24-Stunden-Volumen:
177.86K
Relative Volume:
0.39
Marktkapitalisierung:
$294.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-110.66M
KGV:
-2.1994
EPS:
-3.0963
Netto-Cashflow:
$-97.76M
1W Leistung:
+14.81%
1M Leistung:
+72.51%
6M Leistung:
+228.28%
1J Leistung:
+28.81%
1-Tages-Spanne:
$6.50
$6.94
1-Wochen-Bereich:
$5.30
$7.7299
52-Wochen-Spanne:
$1.78
$7.7299
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Firmenname
Kyverna Therapeutics Inc
Sektor
Branche
Telefon
(510) 626-8331
Adresse
5980 HORTON STREET, EMERYVILLE
Vergleichen Sie KYTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
6.81 | 286.72M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.18 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.62 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.36 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
808.25 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.09 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-05-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-10-09 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-03 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-03-04 | Eingeleitet | JP Morgan | Overweight |
| 2024-03-04 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-03-04 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Kyverna Therapeutics Inc Aktie (KYTX) Neueste Nachrichten
How moving averages guide Kyverna Therapeutics Inc. tradingMarket Growth Summary & Verified Entry Point Detection - newser.com
What MACD signals say about Kyverna Therapeutics Inc.Analyst Upgrade & Weekly High Conviction Ideas - newser.com
Intraday pattern recognizer results for Kyverna Therapeutics Inc.Market Rally & Risk Managed Investment Strategies - newser.com
Kyverna Therapeutics Inc Stock Analysis and ForecastCash Flow Trends & Small Investment Trading Growth - earlytimes.in
Long term hold vs stop loss in Kyverna Therapeutics Inc.Market Performance Report & Growth Focused Investment Plans - newser.com
Historical volatility pattern of Kyverna Therapeutics Inc. visualized2025 Dividend Review & Weekly Top Gainers Alerts - newser.com
Kyverna Therapeutics, Inc. Securities Lawsuit Investigation - Claim Depot
Wells Fargo Maintains Kyverna Therapeutics (KYTX) Overweight Recommendation - Nasdaq
Kyverna Therapeutics stock price target raised to $27 at Wells Fargo - Investing.com
Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsight - GlobeNewswire Inc.
What drives Kyverna Therapeutics Inc stock priceLow Beta Stocks & Join a Community of Smart Investors - earlytimes.in
What’s next for Kyverna Therapeutics Inc. stock priceGold Moves & Detailed Earnings Play Alerts - newser.com
Why retail investors favor Kyverna Therapeutics Inc. stockJuly 2025 WrapUp & Advanced Swing Trade Entry Plans - newser.com
Is Kyverna Therapeutics Inc. forming a bottoming base2025 Major Catalysts & Consistent Profit Alerts - newser.com
Live market analysis of Kyverna Therapeutics Inc.July 2025 Movers & Real-Time Volume Analysis - newser.com
KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Should you hold or exit Kyverna Therapeutics Inc. nowWeekly Market Summary & Momentum Based Trading Ideas - newser.com
Institutional scanner results for Kyverna Therapeutics Inc.2025 Year in Review & Weekly Watchlist for Consistent Profits - newser.com
What analysts say about Kyverna Therapeutics Inc stockGlobal Market Influence & Free Dynamic Capital Growth - earlytimes.in
Kyverna Therapeutics: KYV-101 Heads Toward Phase 3 In MG; Q4 Data In Sight - RTTNews
Goldman Sachs Group Inc. Reduces Stock Position in Kyverna Therapeutics, Inc. $KYTX - Defense World
Kyverna Therapeutics Announces Board Member Resignation - MSN
Kyverna Therapeutics announces board resignation and committee changes - Investing.com India
Kyverna Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Kyverna Therapeutics announces board resignation and committee changes By Investing.com - Investing.com Nigeria
Kyverna Therapeutics stock rating reiterated at Buy by H.C. Wainwright By Investing.com - Investing.com Nigeria
Kyverna’s KYV-101 shows promising results in multiple sclerosis trials By Investing.com - Investing.com Nigeria
Kyverna’s KYV-101 shows promising results in multiple sclerosis trials - Investing.com
Kyverna Therapeutics announces updated data from Phase 1 IITs of KYV-101 - TipRanks
Kyverna Therapeutics Reports Promising Phase 1 Data for KYV-101 in Progressive Multiple Sclerosis, Highlighting CNS Penetration and Clinical Activity - Quiver Quantitative
Kyverna Therapeutics Highlights Potential of KYV-101 in - GlobeNewswire
Breakthrough MS Treatment: Kyverna's CAR T-Cell Therapy Shows CNS Penetration and Disability Improvement - Stock Titan
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS - Sahm
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Block Trades: What is Kyverna Therapeutics Incs book value per share2025 Market Outlook & Real-Time Stock Price Movement Reports - خودرو بانک
Will Kyverna Therapeutics (NASDAQ:KYTX) Spend Its Cash Wisely? - 富途牛牛
Market Fear: Is Kyverna Therapeutics Inc part of any ETF2025 Price Action Summary & Daily Stock Trend Watchlist - khodrobank.com
Finanzdaten der Kyverna Therapeutics Inc-Aktie (KYTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):